Clinical trial
Phase III ALTU-135 CP Safety Trial
NCT00500084 · Anthera Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00500084 |
|---|---|
| Title | Phase III ALTU-135 CP Safety Trial |
| Official title | An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy |
| Acronym | DIGEST CP |
| Lead sponsor | Anthera Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Exocrine Pancreatic Insufficiency |
| Intervention type | Drug |
| Interventions | Liprotamase |
| Enrollment | 39 |
| Start date | Dec 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jul 12, 2007 |
| Last update posted | Oct 24, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: